Monoclonal and recombinant antibodies, 30 years after .. .

摘要: In 1975, the hybridoma technology provided, for first time, an access to murine monoclonal antibodies. During two following decades, their high potential, as laboratory tools, was rapidly exploited, but in vivo applications were still very limited. Nowadays, antibodies, omnipresent both diagnostic and research domains, are largely invading domain of therapy. A wide array novel technologies, including phage display transgenic mice, isolate fully human antibodies engineer these molecules, has been implemented. The natural propensity, antibody metamorphosis makes them ideal response new therapeutic challenges. present review is a tentative update different "formats" walk through techniques recently applied engineering. addition it also addresses some specific issues such development expression systems suitable large-scale production recombinant